Page 10 - Elixir Health Public Relations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJon congletonTom weibleCatalys pacificAdam levyElixir health public relationsMineralys therapeutics incCantor fitzgerald global healthcare conferenceChief executive officer jon congletonChief financial officerChief business officerNew yorkFitzgerald global healthcare conferenceInvestor relationsMineralys therapeutics

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure with a well-tolerated profile – – Enhanced reduction.

United statesTanabe pharmaCatalys pacificLuke laffinDavid rodmanTom weibleMineralys therapeutics incElixir health public relationsDrug administrationVascular thoracic instituteJournal of the american medical associationExchange commissionGlobenewswire incAmerican medical associationBlood pressure disordersThoracic institute

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure , including an enhanced response in individuals with.

United statesTom weibleTanabe pharmaCatalys pacificJon congletonElixir health public relationsDrug administrationMineralys therapeutics incGlobenewswire incAmerican heart associationJournal of the american medical associationExchange commissionAmerican medical associationHeart associationHypertension scientific sessionsChief executive officer

Werth Family Investment Associates Converts $5 8 Million of Debt into Cingulate Equity at a Premium

Werth Family Investment Associates Converts $5 8 Million of Debt into Cingulate Equity at a Premium
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKansas cityPeterj werthMelyssa weibleThomas daltonMatt krepsDarrow associatesExchange commissionSecurities exchangeWerth family investment associatesCingulate incElixir health public relationsCingulate therapeutics llc ctxPrecision timed releaseCingulate therapeuticsNote conversion agreement

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming.

United statesNew yorkRobert andradeLindsay roccoFennec pharmaceuticals incOregon healthElixir health public relationsEuropean commission marketing authorizationScience universityCompany presentationClinical oncology groupDrug administrationExchange commissionFennec pharmaceuticalsGlobal investment conferenceCantor fitzgerald global healthcare conference